trending Market Intelligence /marketintelligence/en/news-insights/trending/1zbyrgadnmniypw3r5xexa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

DBV Technologies raises $172.5M in global offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

DBV Technologies raises $172.5M in global offering

DBV Technologies SA raised about $172.5 million in gross proceeds from a global offering after the underwriters exercised their option to buy additional shares.

As part of the underwriters' option, the French biotechnology company issued 529,162 ordinary shares, including 208,802 ordinary shares in the form of 417,604 American depositary shares.

Each ADS represents the right to receive 0.5 ordinary share. The ADSs were issued at $21.26 apiece in the U.S., Canada and certain non-European countries, while the ordinary shares were sold in in Europe for €34.71 apiece.

DBV's ordinary shares are listed on Euronext Paris under the symbol DBV, while the ADSs are listed on the Nasdaq Global Select Market under the symbol DBVT.

The company plans to use the proceeds to fund the development and commercialization of its allergy treatment Viaskin Peanut, to advance the development of other product candidates and for working capital and general corporate purposes.

Morgan Stanley and Goldman Sachs acted as joint lead book-running managers, while Barclays and Deutsche Bank Securities also served as book-running managers for the offering. Bryan Garnier & Co. acted as a co-manager for the offering.